Evaluation of molecular monitoring and response milestone of patients with chronic myeloid leukemia to tyrosine kinase inhibitors in Middle Euphrates of Iraq

Rahem, Rahem M; Alaawad, Alaa Sadeq; Kamoona, Talib Hussein

doi:10.4103/2072-8069.198080

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, 45.3% of CML patients did not show optimal molecular response. Likewise Rahem, et.al also reported that more than 50% of CML patients undergoing kinase inhibitor therapy achieved optimal molecular response (Rahem et al, 2016). The optimal molecular response predicts that CML patients can live longer (Rajabto et al, 2022).…”

Section: Resultsmentioning

confidence: 99%

Differences In Hematology And Bcr-Abl Molecular Profiles In Patients With Chronic Myeloid Leukemia Undergoing Tyrosine Kinase Inhibitor Therapy

Santosa

Shidqi

Muslim³

et al. 2022

Med.Lab.Tech.J.

View full text Add to dashboard Cite

Chronic myeloid leukemia (CML) is a myeloproliferative malignancy due to the formation of the BCR-ABL fusion gene in chronic myeloid leukemia. This condition causes excessive cell proliferation, resulting in an increase in the number of leukocytes. Tyrosine Kinase Inhibitor (TKI) is a first-line therapy that helps reduce the percentage of the BCR-ABL fusion gene in patients with chronic myeloid leukemia. This study was conducted to determine differences in the hematological profiles (hemoglobin levels, leukocyte counts, platelet counts) and molecular BCR-ABL in patients with chronic myeloid leukemia before and after 12 months of tyrosine kinase inhibitors therapy. This analytic observational study was administered using a cross-sectional design to in analyzing the medical records of CML patients who underwent TKI therapy at the Sub Specialist Polyclinic of Internal Medicine Hematology Oncology Ulin Banjarmasin Regional Hospital from March 2021-April 2022. Dependent T-test and McNemar's test were performed in data analysis which results showed that 12 month tyrosine kinase inhibitor therapy could increase the hemoglobin levels, decrease leukocyte counts, platelet counts as well as decreasing the percentage of BCR-ABL gene fusion in patients with chronic myeloid leukemia. In conclusion, significant differences were found in the hematological profiles (p<0.001) and the molecular BCR-ABL (p<0.001) before and after 12 months of tyrosine kinase inhibitor therapy

show abstract

Section: Resultsmentioning

confidence: 99%

Differences In Hematology And Bcr-Abl Molecular Profiles In Patients With Chronic Myeloid Leukemia Undergoing Tyrosine Kinase Inhibitor Therapy

Santosa

Shidqi

Muslim³

et al. 2022

Med.Lab.Tech.J.

View full text Add to dashboard Cite

show abstract

“…Fluorescence in situ hybridization (FISH) and reverse transcription real-time polymerase chain reaction RT-RT qPCR can be used on peripheral blood or bone marrow aspirate, flow cytometry is identifying cases with unrecognized progression to lymphoid blast crisis by their phenotypic features while karyotyping may identify some cytogenetic abnormalities (Jabbour E. and Kantrjian H 2018). Malignancies of the blood characterized by genetic translocation which can be used as tumour markers while monitoring the response to therapy (Rahem MR., Alaawad AS., and Kamoona TH 2018). The use of real-time PCR qPCR is becoming an important research tool for the detection of the molecular event and guide therapeutic decision based on how the patient responded at the molecular level.…”

Section: Introductionmentioning

confidence: 99%

Detection of BCR-ABL gene in Chronic Myeloid Leukemia patients treated with Tyrosine Kinase Inhibitors Drugs by Gene Expert System

Khaleq¹,

Saheb²,

Sultan³

et al. 2019

ijrps

View full text Add to dashboard Cite

Chronic myeloid leukaemia (CML) is one of the human fatalities caused by genetic mutation and chromosomal translocation, a BCR-ABL fusion gene and as a result, Philadelphia chromosome is formed. The irregular tyrosine kinase activity of the encoded protein by this gene causes the establishment of the disease. This study was conducted at the period from September 2016 to February 2017,100 Iraqi CML patients were divided into two groups, first group of 50 patients were received Imatinib 400-800 mg/day, second group of another 50 patients were received 800 mg/day Nilotinib, WBC were microscopically counted using improved Neubauer ruled hemocytometer counting chamber. The results of WBC count in different disease duration and stages of treatment in the group of patients treated with Imatinib showed that highest WBC count was observed in newly diagnosed patients while there was a significant reduction in the WBC count after one month, after one year and final dose of treatment were 11.8, 6.4 and 8.1 respectively, on the other hand the results of WBC count in the group of patients treated with Nilotinib showed that the highest WBC count was observed in newly diagnosed patients 87.54± 8.71 whereas the WBC count after one month, one year and at the final dose of treatment were 7.3, 6.8, 7.9 respectively with significant reduction in the WBC count. The results of the CML patient’s distribution according to BCR-ABL gene analysis in the patient's group treated with Imatinib showed that high concentration in newly diagnosed patients 4.753 as compared with significant reduction with other stages of treatment after one month and after one year 0.94 and 0.09 respectively.

show abstract

Evaluation of molecular monitoring and response milestone of patients with chronic myeloid leukemia to tyrosine kinase inhibitors in Middle Euphrates of Iraq

Cited by 2 publications

References 0 publications

Differences In Hematology And Bcr-Abl Molecular Profiles In Patients With Chronic Myeloid Leukemia Undergoing Tyrosine Kinase Inhibitor Therapy

Differences In Hematology And Bcr-Abl Molecular Profiles In Patients With Chronic Myeloid Leukemia Undergoing Tyrosine Kinase Inhibitor Therapy

Detection of BCR-ABL gene in Chronic Myeloid Leukemia patients treated with Tyrosine Kinase Inhibitors Drugs by Gene Expert System

Contact Info

Product

Resources

About